Gwenn Hansen - Feb 14, 2023 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Scientific Officer
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen
Stock symbol
NRIX
Transactions as of
Feb 14, 2023
Transactions value $
$0
Form type
4
Date filed
2/15/2023, 03:10 PM
Previous filing
Feb 1, 2023
Next filing
May 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Award $0 +88.9K $0.00 88.9K Feb 14, 2023 Common Stock 88.9K $10.83 Direct F1
transaction NRIX Restricted Stock Units Award $0 +24K $0.00 24K Feb 14, 2023 Common Stock 24K $0.00 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/36 of the total shares monthly beginning March 14, 2023 until the option is fully vested on February 14, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.
F3 The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on April 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
F4 RSUs do not expire; they either vest or are canceled prior to the vest date.

Remarks:

Exhibit 24 - Power of Attorney